Avatrombopag

Drug Profile

Avatrombopag

Alternative Names: AKR-501; AKR-501 monomaleate; AVA; Avatrombopag maleate; E-5501; YM-477

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Dova Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Thrombocytopenia
  • Phase III Idiopathic thrombocytopenic purpura

Most Recent Events

  • 22 Sep 2017 Preregistration for Thrombocytopenia in USA (PO)
  • 10 Aug 2017 Dova announces intention to submit NDA to US FDA for Thrombocytopenia in Q3 2017
  • 10 Aug 2017 Dovo Pharmaceuticals intends to launch avatrombopag in USA in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top